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Abstract
Rationale Lithium remains the most effective treatment for
bipolar disorder and also has important effects to lower sui-
cidal behaviour, a property that may be linked to its ability to
diminish impulsive, aggressive behaviour. The antioxidant
drug, ebselen, has been proposed as a possible lithium-
mimetic based on its ability in animals to inhibit inositol
monophosphatase (IMPase), an action which it shares with
lithium.
Objectives The aim of the study was to determine whether
treatment with ebselen altered emotional processing and di-
minished measures of risk-taking behaviour.
Methods We studied 20 healthy participants who were tested
on two occasions receiving either ebselen (3600mg over 24 h)
or identical placebo in a double-blind, randomized, cross-over
design. Three hours after the final dose of ebselen/placebo,
participants completed the Cambridge Gambling Task
(CGT) and a task that required the detection of emotional
facial expressions (facial emotion recognition task (FERT)).
Results On the CGT, relative to placebo, ebselen reduced de-
lay aversion while on the FERT, it increased the recognition of
positive vs negative facial expressions.
Conclusions The study suggests that at the dosage used,
ebselen can decrease impulsivity and produce a positive bias
in emotional processing. These findings have implications for
the possible use of ebselen in the disorders characterized by
impulsive behaviour and dysphoric mood.
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Introduction
Lithium is best known for its ability to treat acute mania and
prevent the recurrence of both mania and depression in pa-
tients with bipolar disorder. In addition, lithium is the only
psychotropic drug shown reliably to decrease suicidal behav-
iour (Geddes et al. 2010; Cipriani et al. 2013; Miura et al.
2014), an effect which does not appear to be accounted for
solely by its ability to diminish mood disturbance (Cipriani
et al. 2013). Consistent with this, a number of studies in non-
bipolar patients have shown that lithium decreases the inci-
dence of impulsive aggression (Sheard et al. 1976; Craft et al.
1987; Jones et al. 2011). Such an effect could be important in
the management of disorders that have been linked to violent
behaviour towards the self and/or others. However, lithium
treatment has several drawbacks including poor tolerance, a
narrow therapeutic index (resulting in the requirement for
blood monitoring) as well as longer-term toxicity, particularly
for the kidney (McKnight et al. 2012; Shine et al. 2015).
Therefore, a form of drug treatment which has the efficacy
of lithium but without its toxicity could be a worthwhile de-
velopment in the management of impulsive aggression.
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Rational design of a lithium-like agent could be pursued
based on its mechanism of action, but lithium’s therapeutic
target remains unclear. Based on clinically relevant lithium
concentrations (0.6–1.2 mM), the two most likely targets are
glycogen synthase kinase 3 and inositol monophosphatase
(IMPase) (Berridge et al. 1989; Belmaker et al. 1996; Agam
et al. 2009). Recently, we reported inhibition of IMPase by
ebselen (IC50 1.5 μM), a bioavailable antioxidant drug that
has been tested in humans for other diseases including post-
stroke neuroprotection and noise-induced hearing loss (Singh
et al. 2013; Lynch and Kil 2009; Azad and Tomar 2014).
Using magnetic resonance spectroscopy (MRS), we have
previously found that ebselen treatment lowers inositol levels
in anterior cingulate cortex in healthy participants (Singh et al.
2015), suggesting inhibition of IMPase by ebselen in humans.
In the same investigation, we found that ebselen altered emo-
tional processing by increasing the accuracy of recognition of
facial expressions of happiness and disgust in the facial emo-
tion recognition task (FERT). We also found that ebselen de-
creased learning through reward reinforcement in a probabi-
listic learning task (Singh et al. 2015). The aim of the present
study was to assess further the neuropsychological effects of
ebselen by studying the effects of higher dose of ebselen on
the FERT and in the Cambridge Gambling Task which as-
sesses reward-seeking behaviour outside of a learning context
(Rogers et al. 1999; Clark et al. 2008).
Methods
Participants and study design
Ethical approval for the study was obtained from the National
Research Ethics Service Committee (NRES), South-Central
Oxford B. Twenty healthy participants (7 females, 13 males,
mean age 25.1 years, range 20–38 years; mean BMI 22.7 kg/
m2, range 18.7–30.0 kg/m2) were included in the study after
giving full informed written consent. Exclusion criteria in-
cluded a history of any DSM-V Axis I psychiatric disorder
(determined using the Standard Clinical Interview for
Diagnostic and Statistical Manual for Mental Health
Disorders), significant current medical condition, current reg-
ular medication (apart from the contraceptive pill), pregnancy
or lactation, heavy smoking (defined as more than five ciga-
rettes per day) and having taken part in another study involv-
ing an investigational drug within the last 3 months.
Participants were asked to maintain stable exercise and diet
as well as refrain from alcohol during study participation.
Ebselen capsules and identical matching placebo (contain-
ing microcrystalline cellulose) were purchased from Shasun
Pharmaceuticals Ltd. Participants were tested twice (7 days
apart) receiving on one occasion ebselen and on the other
placebo in a randomized, double-blind, cross-over design.
Ebselen was administered in 6× 200 mg capsules in three
doses given over 2 days.
On the day before cognitive testing, participants took the
first dose at 1 pm and the second dose at 10 pm. The final dose
was taken around 3 h prior to cognitive testing. Participants
were sent text message reminders a few minutes before they
were due to take medication and were asked to confirm re-
ceiving the messages. The cognitive tasks were carried out
immediately after a magnetic resonance spectroscopy study,
the results of which have been reported separately (Masaki
et al. 2016).
Mood, personality and sleep questionnaires
On the screening visit, participants were assessed for baseline
depression and anxiety symptoms with the Beck Depression
Inventory (Beck et al. 1961) and the state measure of the State-
Trait Anxiety Inventory (STAI) (Spielberger et al. 1983), and
for personality with the Eysenck Personality Questionnaire
(Eysenck and Eysenck 1975). On the morning preceding psy-
chological testing, the Leeds Sleep Evaluation Questionnaire
(LSEQ) was completed within 30 min of waking (Parrott and
Hindmarch 1980). Before cognitive testing, participants were
asked to rate their mood using the Positive and Negative
Affective Schedule (PANAS) (Watson et al. 1988), to com-
plete a side effect profile using a 4-point rating scale and also
to guess as to whether they had received ebselen or placebo on
that randomization arm.
Cambridge Gambling Task
The Cambridge Gambling Task (CGT) from the Cambridge
Neuropsychological Test Automated Battery (CANTAB, ver-
sion 3.0.0, Cambridge Cognition Ltd., Cambridge, UK)
(Rogers et al. 1999; Clark et al. 2008) assesses decision-
making and risk-taking behaviour outside a learning context.
In each trial, participants are shown ten boxes at the top of the
screen, with some boxes being red and some being blue. The
ratio of red to blue boxes varies from 9:1, 8:2, 7:3, 6:4, 5:5 and
vice versa in a pseudo-random order. Participants are informed
that a yellow token is hidden inside one of the boxes and asked
to indicate the colour box in which the token is most likely to
be hidden, by pressing the colour (RED or BLUE) in a re-
sponse panel at the bottom of the screen. Following their re-
sponse, the participants indicate confidence in their selection
by betting a proportion of points they are allocated (starting
with 100 points). Besides confidence in selection, this mea-
sure also assesses the willingness to risk the points they al-
ready possess or have accumulated for further real or per-
ceived reward. On each trial, five bets are offered, and each
bet represents a fixed percentage of the current total points
score (5, 25, 50, 75 and 95 %). Possible bets are presented
sequentially in a box on the right of the display and
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participants touch the box to select the bet. If correct, the bet
value is added to their total points on the left of the panel, and
if incorrect, it is subtracted from the total points. Participants
are asked to accumulate as many points as possible. Following
the response, the location of the token is revealed.
Participants perform the task in four blocks of two separate
conditions, ascending and descending bet value (the condition
order is counterbalanced across participants). In the ascending
condition, bets increase at 2.5-s time intervals from 5 to 95 %
until participants make their selection. This means that if a
participant bets at the first value presented, then they bet only
5 % of their total points, and if they wait for the highest value,
they bet 95% of their total points. In the descending condition,
bets start from 95 % and decrease to 5 %. Low bets in the
ascend condition and high bets in the descend condition reveal
an impulsive betting strategy, while high bets in both condi-
tions reveal a risk-taking or reward-seeking strategy.
From the first stage of the task (selecting the likely colour
of the box in which the token is hidden), the outcome mea-
sures are deliberation time and quality of decision-making.
Deliberation time is the mean latency from the presentation
of coloured boxes to participant selection. Quality of decision-
making refers to the proportion of trials on which the more
likely outcome is chosen. From the gamble stage, the outcome
measures are risk taking, risk adjustment and delay aversion.
Risk taking refers to the mean proportion of current points that
the subject stakes on each gamble when the more likely out-
come is selected, and can be regarded as an index of reward
seeking or loss aversion. Risk adjustment measures the degree
to which a subject varies their risk taking in response to the
ratio of red to blue boxes on each trial. Delay aversion is the
difference between the risk-taking score in the descend and
the ascend condition.
Facial emotion recognition task
The facial emotion recognition task (FERT) featured six basic
emotions—happiness, surprise, sadness, fear, anger and dis-
gust—taken from the Pictures of Affect Series (Ekman and
Friesen 1976). These facial expressions had been morphed
between each prototype and neutral using techniques de-
scribed by Young et al. (1997). Morphing involves taking a
variable percentage of the shape and texture differences be-
tween the two standard images 0 % (neutral) and 100 % (full
emotion) in 10 % steps.
Four examples of each emotion at each intensity were pre-
sented (from a total set total of ten individuals). Each face was
also shown in a neutral expression, giving a total of 250 stim-
ulus presentations. Subjects were asked to assess the facial
expression of presented faces as quickly and accurately as pos-
sible by pressing one of seven labelled keys. Subjects were
informed that facial expression from each category would ap-
pear, including neutral, but also that faces would contain
different levels of each emotion. Facial stimuli were presented
in a random order on a laptop screen for 500 ms then replaced
by a blank screen during which time subjects responded. The
task was broken down into two parts with an untimed rest
period between them. The number of stimuli accurately classi-
fied as each emotion, as well as the number incorrectly
assigned to each emotion, and reaction times were recorded.
The primary outcome measure was the effect of ebselen vs
placebo on the accuracy to detect positive (happy+ surprise)
vs negative (sad + fear + disgust + anger) facial expressions
(Post et al. 2015).
Statistics
Statistical analyses were performed in SPSS version 22. For
the CGT, analyses were conducted with repeated-measures
ANOVA with ‘treatment’ (ebselen vs placebo) and ‘order’
(placebo first vs ebselen first) as within-subject factors. A
similar analysis was carried out for the FERT but ‘emotion’
(positive versus negative facial expression) was added as a
further within-subject factor. Significant differences on the
ANOVA were followed up with pairwise comparisons using
paired samples t tests.
Results
Subjective state, energy and side effects
At baseline, all participants had low scores on self-rating
scales of mood and anxiety (Table S1). There were no main
or interactive effects of treatment on mood, assessed using
PANAS questionnaire (Table 1). Ebselen was well tolerated
and no participants dropped out of the study. Five participants
reported feeling drowsywhile on ebselen treatment, compared
with none reporting this effect while on placebo treatment.
Otherwise, there was a low and comparable frequency of side
effects reported during ebselen and placebo treatment
(Figure S1). There were no significant differences in the sub-
jective measures of sleep assessed using the LSEQ
(Figure S2). Participants were more likely to guess correctly
that they had received placebo in comparison to ebselen, but
the difference was of borderline significance (Table 1).
Cambridge Gambling Task
There were no significant effects of treatment on the quality of
decision-making, deliberation time or risk adjustment
(Table 2). Ebselen treatment was associated with a significant
decrease in delay aversion (F1, 18= 8.21, p=0.010). This ef-
fect was present irrespective of the probability of a favourable
outcome (ratio of the bets presented) (Fig. 1). Ebselen treat-
ment was also associated with an increase in reward seeking
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(risk taking) (F1, 18= 4.61 p=0.046). There was significant
interaction between order and treatment on deliberation time
(F1, 18 = 38.41, p=0.001). There were no other significant
main or interactive effects of order on the remaining measures
on the CGT.
Facial emotion recognition task
There was a significant interaction between treatment and
emotion for the accuracy of recognition of positive vs negative
facial expressions (F1, 18 = 8.27, p = 0.010). Follow-up
pairwise comparisons revealed that ebselen treatment signifi-
cantly increased the accuracy of recognition of positive ex-
pressions (p=0.035), without significant effects on negative
expressions (p=0.38) (Fig. 2). When considering the accura-
cy of recognition of individual facial expressions, there was a
trend towards significant interactions between treatment and
emotion (F5, 90= 2.15, p=0.067). Follow-up pairwise com-
parisons revealed that ebselen treatment improved the accura-
cy of recognition of happy facial expressions (p=0.033) with-
out significant effects on the accuracy of recognition of other
emotional expressions (Figure S3, Table S2). Ebselen treat-
ment did not affect the speed to respond to facial expressions
or the number of misclassifications (Fig. 2).
There was no significant main effect of order on the
accuracy of recognizing positive and negative facial ex-
pressions (F1, 18 = 0.27, p= 0.61), but there was a signifi-
cant interaction between order and treatment when consid-
ering accuracy of facial emotion recognition (F1, 18 = 6.34,
p= 0.022). However, there was no significant three-way
interaction between order, treatment and emotion (F1,
18 = 0.012, p= 0.91).
Discussion
Our findings show that short-term treatment with ebselen di-
minishes a laboratory measure of impulsivity and produces a
positive bias in emotional processing as measured by the
FERT. Based on its ability to inhibit IMPase, ebselen has been
proposed as a putative lithium-mimetic, and short-term treat-
ment with ebselen in healthy participants decreased levels of
inositol in anterior cingulate cortex, as measured by MRS
(Singh et al. 2015). This has been confirmed as part of the
present study (Masaki et al. 2016). This is consistent with
IMPase inhibition in the brain in humans. At the doses
employed and for the short period of time during which treat-
ment was administered, ebselen appeared well tolerated and
the only side effect apparently distinguishing it from placebo
was drowsiness.
The CGT provides measures of decision-making as well as
impulsive responding. The latter (‘delay aversion’) is mea-
sured by subtracting the bets made on ascending trials from
those of the descending trials. In this task, low bets in the
ascend condition coupled with high bets in the descend con-
dition reveal a more impulsive form of responding and this
difference in bets on the two conditions was diminished by
ebselen suggesting a decrease in impulsivity. Interestingly,
patients at risk of bipolar disorder by virtue of a positive fam-
ily history, or high score on the Hypomanic Personality Scale,
demonstrate increased delay aversion on the CGT (Wessa
et al. 2015).
The observation that ebselen diminishes impulsivity on the
CGT is also of interest in view of the clinical effect of lithium
to decrease rates of suicide in patients with recurrent mood
disorder (Cipriani et al. 2013). Part of this effect is no doubt
Table 1 Subjective mood ratings using the positive and negative affective schedule (PANAS) questionnaire, during placebo and ebselen study visits.






PANAS—positive 28.5 ± 1.6 29.8 ± 1.2 F1, 19 = 1.7, p= 0.204*
PANAS—negative 11.8 ± 0.7 11.9 ± 0.7 F1, 19 = 0.1, p= 0.818*
Correct guesses for randomization 14/20 (70 %) 7/20 (35 %) p= 0.056 (χ2)**
*Repeated measures ANOVA; **chi-squared statistic









Delay aversion (%) 13.7 ± 2.19 9.0 ± 2.14 F1, 18 = 8.21, p = 0.010
Reward seeking (%) 60.3 ± 1.82 63.9 ± 1.45 F1, 18 = 4.61, p = 0.046
Deliberation time (ms) 1475± 99 1408± 78 F1, 18 = 2.50, p = 0.131
Quality of decision-making (%) 98.3 ± 0.8 99.3 ± 0.3 F1, 18 = 0.20, p = 0.155
Risk adjustment 2.3 ± 0.15 2.1 ± 0.18 F1, 18 = 2.88, p = 0.107
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due to the action of lithium to diminish the risk of episodes of
severe depression. However, lithium appears to have a greater
benefit to reduce suicidality than other equally effective
mood-stabilizing drugs (Cipriani et al. 2013). In addition, lith-
ium lowers suicidal behaviour even in patients who do not
respond well to its mood-stabilizing effects (Ahrens and
Müller-Oerlinghausen 2001). This has given rise to the sug-
gestion that part of the reason for lithium’s ability to reduce
suicidal behaviour stems from additional neuropsychological
actions to inhibit impulsivity and aggression, and work in
animal models shows that lithium can indeed produce such
effects (O’Donnell and Gould 2007; Ohmura et al. 2012).
There are also clinical studies showing that lithium can de-
crease impulsive aggression in non-mood disorder patient
populations (Sheard et al. 1976; Craft et al. 1987; O’Donnell
and Gould 2007; Jones et al. 2011).
The CGT also provides a measure of risk taking calculated
from the proportion of points bet on the gambles with a greater
likelihood of a positive outcome. This has been taken as a
measure of reward seeking or loss aversion. Depressed patients
and those at risk of depression characteristically have lower
reward seeking on the CGT (Murphy et al. 2001; Rawal et al.
2013; Mannie et al. 2015), the opposite of the effect produced
by ebselen. This might suggest a potential antidepressant effect
Fig. 1 Results of the Cambridge Gambling Task. a Ebselen treatment
was associated with a significant decrease in the mean delay aversion
(main effect of treatment on ANOVA, F1, 18 = 8.208, p = 0.010). b The
decrease in delay aversion following ebselen treatment was present
irrespective of the token ratio presented
Fig. 2 Results of the Facial Emotion Recognition Task. a There were
significant interactions between treatment and emotion, for accuracy of
recognition of positive and negative facial expressions (F1, 18 = 8.267,
p= 0.010). Ebselen treatment was associated with a significant increase
in the accuracy of recognition of positive expressions without significant
effects in recognition of negative expressions. b Ebselen treatment was
not associated with any significant differences in the misclassifications of
emotional expressions. All data are plotted as mean ± standard error of
mean, N= 20. Values represent the percentage of average total responses
for positive (happy + surprise) and negative (angry + disgust + fear + sad)
expressions. *p= 0.035
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of ebselen. To the best of our knowledge, the effect of lithium
has not been studied specifically in the CGT but clinically
lithium is not usually regarded as a useful acute antidepressant
agent when used as monotherapy. However, lithium can have
antidepressant effects when added to ineffective antidepressant
medication in patients with resistant depression (Nelson et al.
2014). In our previous study, we found evidence for decreased
reinforcement learning after ebselen treatment (Singh et al.
2015). The CGT provides a measure of reward responding
which is independent of learning (Rogers et al. 1999; Clark
et al. 2008). This suggests that the effect of ebselen on rein-
forcement learning is not mediated by devaluation of reward.
The effects of ebselen on the FERTalso suggest a potential
antidepressant action. Negative biases in emotional process-
ing are well characterized in depression (Disner et al. 2011),
and conventional antidepressants have been shown to produce
a positive shift in emotional processing in healthy participants
as measured by the FERT (Harmer et al. 2008, 2009; Arnone
et al. 2009). A similar effect has been described with novel
antidepressants including agomelatine and a nociceptin recep-
tor antagonist (Harmer et al. 2011; Post et al. 2015).
In our previous study of ebselen, we found an increased
accuracy of recognition of happy facial expressions but also
disgust (Singh et al. 2015) which was not apparent in the
present investigation. We are uncertain of the reason for this,
but it may reflect differences in experimental design. In our
earlier study, the effect of ebselen on the FERT was studied
using a parallel group, placebo-controlled design rather than
the cross-over design used here, which raises a potential in-
fluence of order effects. Also the dose of ebselen in the pres-
ent study was twice that used previously (Singh et al. 2015).
In the present study, we found no main effect of order on the
accuracy of recognition of positive and negative faces, though
a previous investigation of the FERT did report an increased
ability to discriminate expressions of happiness and disgust
following repeat testing after an interval of 1 week (Adams
et al. 2015). However, we found no interaction between order,
emotion and treatment in the present study. Also because the
order of ebselen and placebo administration was randomized,
we think it is unlikely that order/learning effects played a
significant role in the ability of ebselen to increase the recog-
nition of positive facial expressions in the FERT.
In conclusion, ebselen is a potential lithium-mimetic which
appears to decrease impulsivity on the CGT. This effect is of
particular interest in view of the action of lithium to decrease
impulsivity in animal studies and impulsive aggression and
suicide in patient populations.
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